Mohnark Pharmaceuticals Recalls Lidocaine Topical Anesthetic Cream Due to Failure to Meet Child-Resistant Packaging Requirement; Risk of Poisoning (Recall Alert)

Recall Insight

This CPSC action (record #22754) was formally reported on June 30, 2022. It is classified under Moderate severity, with a current status of Active. Mohnark Pharmaceuticals Inc., of Davie, Fla. is listed as the recalling firm. Federal records indicate About 9,000 units are affected.

The documented reason for this recall is: The product contains lidocaine which must be in child resistant packaging as required by the Poison Prevention Packaging Act (PPPA). The packaging is not child resistant, posing a risk of poisoning to young children if … Distribution information was not included in the agency filing, so consumers should assume broad potential exposure until the firm publishes point-of-sale details. The remedy documented by the agency is: Consumers should immediately stop using the recalled cream and store it in a location out of sight and reach of children. Contact Mohnark Pharmaceuticals for instructions on how to dispose of the pro… — consumers holding this product should act on that instruction rather than relying on general guidance.

To put this record in context, PlainRecalls indexes 83,949 recalls across the FDA, CPSC, NHTSA and USDA FSIS going back to 1995. Within the same product category, the database holds 6 closely related recalls, of which 1 were also issued by CPSC. That clustering is a signal — repeated actions in a narrow category often indicate a systemic quality-control issue, a supplier-wide contamination, or a design defect that has propagated across product lines. This recall is roughly 4 years old; older recalls can remain relevant because many units enter resale, rental, and secondary-market channels where the original warning never reaches the end user. Always cross-check the recall number against the official agency page before relying on any summary.